Arecor enters formulation partnership with Skye Bioscience
19th May 2025 11:59
(Sharecast News) - Arecor Therapeutics announced on Monday that it has entered a formulation development partnership with Skye Bioscience to create an improved version of Skye's investigational obesity treatment, nimacimab.
Read moreArecor enters collaboration with unnamed global pharma major
26th Mar 2025 14:51
(Sharecast News) - Arecor Therapeutics announced on Wednesday that it has entered into a new collaboration with a major global pharmaceutical company to apply its proprietary Arestat technology platform to develop an enhanced formulation of the partner's proprietary product.
Read moreRevenue higher, cash reserves fall at Arecor
3rd Feb 2025 14:40
(Sharecast News) - Arecor Therapeutics reported total full-year revenue of £5.1m in a trading update on Monday, up from £4.6m in 2023.
Read moreArecor to wind up operations at Tetris Pharma subsidiary
10th Jan 2025 14:59
(Sharecast News) - Arecor Therapeutics announced plans to cease operations within its subsidiary Tetris Pharma during 2025 on Friday, adding that it had mutually agreed with Xeris BioPharma to return the rights to Ogluo - a ready-to-use glucagon auto-injector for severe hypoglycemia.
Read moreArecor upbeat on signing of exclusive licensing deal
30th Dec 2024 10:05
(Sharecast News) - Arecor Therapeutics announced the signing of an exclusive licensing agreement for AT351, a ready-to-dilute (RTD) liquid formulation of a widely-used critical care therapy, with a subsidiary of a leading global pharmaceutical-focused chemicals marketing company on Monday.
Read moreArecor Therapeutics shares tank on funding update
10th Jun 2024 07:52
(Sharecast News) - The share price of AIM-listed Arecor Therapeutics dropped by almost a third on Monday after the biopharma firm warned that its working capital requirements had "accelerated" while full-year revenues remain highly uncertain.
Read moreArecor subsidiary Tetris launching Ogluo in the Netherlands
29th Feb 2024 14:12
(Sharecast News) - Arecor Therapeutics updated the market on an announcement made by its subsidiary Tetris Pharma on Thursday, regarding the launch of the 'Ogluo' glucagon prefilled autoinjector pen in the Netherlands.
Read moreArecor appoints new commercial manager to Tetris subsidiary
3rd Jan 2024 13:44
(Sharecast News) - Arecor Therapeutics announced the appointment of Dr Helen Parris as senior vice president and commercial and general manager of its subsidiary Tetris Pharma on Wednesday.
Read moreArecor inks co-development deal with global medicine company
4th Dec 2023 09:49
(Sharecast News) - Arecor Therapeutics announced a co-development and exclusive licence option agreement with an unnamed global medical products company on Monday.
Read moreArecor gets milestone payment from Arestat partner
17th Nov 2023 12:06
(Sharecast News) - Arecor Therapeutics announced a significant milestone in its collaboration with a global pharmaceutical partner on Friday.
Read moreArecor inks partnership with unnamed pharma giant
17th Aug 2023 15:55
(Sharecast News) - Biopharmaceutical company Arecor Therapeutics has entered into a partnership agreement with an unnamed global top-10 pharmaceutical company, it announced on Thursday.
Read moreArecor Therapeutics appoints new chief business officer
5th Apr 2023 14:07
(Sharecast News) - Biopharmaceutical company Arecor Therapeutics announced the appointment of Dr Manjit Rahelu as its chief business officer on Wednesday.
Read moreArecor Therapeutics begins type-2 diabetes trial
22nd Mar 2023 17:01
(Sharecast News) - Arecor Therapeutics announced the start of the phase one clinical trial for its ultra-rapid acting insulin candidate 'AT278' on Wednesday, with the first patient being dosed.
Read moreArecor granted three patents in US, India
16th Feb 2023 18:11
(Sharecast News) - Biopharmaceutical company Arecor Therapeutics has received patents for its novel formulations of insulin and adalimumab, it announced on Thursday.
Read moreArecor ends 2022 in line with forecasts
19th Jan 2023 16:05
(Sharecast News) - Biopharmaceutical company Arecor Therapeutics said in an update on Thursday that its financial performance for 2022 was in line with market expectations, as it closed the period with an unaudited cash balance of £12.8m.
Read more